Rizatriptan for Migraine: How It Works, Evidence, and Safety

Rizatriptan is an acute, or abortive, migraine drug, meaning it is taken to stop an attack that has already begun. It does not lower how often attacks happen, and it is not taken every day as a preventive. People who have frequent migraines often pair an acute drug like rizatriptan with a separate preventive medicine that they take daily.

It is a triptan, the class of drugs designed for migraine that our explainer on how triptans work covers in full. The FDA approved rizatriptan under the brand name Maxalt for acute treatment of migraine in adults in 1998. It now sells as an inexpensive generic. It comes as a standard swallowed tablet and as an orally disintegrating tablet, branded Maxalt-MLT, that melts on the tongue.

Rizatriptan acts on serotonin receptors in and around the brain to switch off a migraine attack. It is a selective agonist at the 5-HT1B and 5-HT1D receptors, which means it binds to and activates these two receptor types and largely leaves others alone. This is the same mechanism sumatriptan uses, so the two drugs belong to one class.

Two actions matter. Through 5-HT1B receptors on blood vessels, rizatriptan constricts cranial vessels that have widened during an attack. Through 5-HT1D receptors on trigeminal nerve endings, it blocks the release of inflammatory neuropeptides, including calcitonin gene-related peptide (CGRP), that drive migraine pain. Together these interrupt the attack rather than just dull the pain.

The vessel-narrowing action is also the source of the drug's main safety concern. Rizatriptan does not narrow only the vessels around the brain, so it is avoided in people whose hearts or other arteries cannot tolerate any added constriction.

Rizatriptan ranks among the strongest oral triptans, and the clearest comparison comes from a large meta-analysis. Researchers pooled 53 trials in over 24,000 people and used sumatriptan 100 mg, the oldest and best-studied oral triptan, as the benchmark (Ferrari 2001). At that benchmark, about 59% of people reached headache relief at two hours and about 29% became fully pain-free.

Against that benchmark, rizatriptan 10 mg showed better efficacy and more consistent results across attacks, with similar tolerability. Consistency means the drug worked in at least two of three treated attacks, which matters for a treatment people reach for again and again. In the same analysis, rizatriptan 10 mg sat in the top group of oral triptans for the likelihood of consistent success.

Onset is relatively fast among the oral triptans, which is part of why people favor it. Major guidelines reflect the broader evidence. The American Headache Society's 2021 consensus statement places triptans among the first-line options for treating moderate to severe migraine attacks, and for milder attacks that do not respond to simple pain relievers (Ailani 2021). Rizatriptan is one of the triptans that recommendation covers.

Rizatriptan comes in two forms that work about the same, with one common misconception worth clearing up. The standard tablet is swallowed with water. Maxalt-MLT, the orally disintegrating tablet, dissolves on the tongue and can be taken without water, which helps when an attack brings nausea or a person is away from a glass.

The melt is not the faster option. The FDA label reports that the two forms reach a similar peak blood level and a similar overall exposure, but the melt is absorbed somewhat more slowly, with the peak delayed by up to about 0.7 hour. The melt's advantage is convenience, not speed. Anyone choosing it for a quicker effect is choosing it for the wrong reason.

The usual rizatriptan dose is 5 mg or 10 mg taken at the start of an attack, and the 10 mg dose tends to work better. If the attack responds and then comes back, a second dose may be taken after two hours, up to a maximum of 30 mg in 24 hours. If the first dose does nothing at all, a second dose of the same drug usually will not help that attack.

Propranolol changes the math. Propranolol is a beta blocker used to prevent migraine, and it slows how the body clears rizatriptan, raising rizatriptan blood levels by about 70% (FDA label). For that reason the label caps the dose at 5 mg in anyone taking propranolol, limits the total to three 5 mg doses in 24 hours, and advises spacing the two drugs. If you take propranolol, tell the clinician prescribing rizatriptan so the dose is set correctly.

Like all triptans, rizatriptan works best taken early in an attack, at mild pain, before the headache builds and the scalp turns tender. Treating at the first sign gives the drug its best chance.

Most people tolerate rizatriptan, and the common side effects are mild and short-lived. Many people feel tingling, warmth, or flushing soon after a dose, sometimes called triptan sensations. A tight or heavy feeling in the chest, throat, or jaw is also common and is usually not coming from the heart, though it can be unsettling the first time. Dizziness, drowsiness, and dry mouth can also occur.

One detail matters for a specific group. Maxalt-MLT, the melt form, contains aspartame and so contains phenylalanine, about 2.8 mg per tablet. People with phenylketonuria (PKU) must account for any phenylalanine source, so they should use the standard tablet rather than the melt or discuss it with their clinician first.

Using acute migraine drugs too often can backfire and cause medication-overuse headache, a pattern of rebound headaches that builds when these drugs are taken on roughly ten or more days a month. The fix is to cap how often the acute drug is used and, for frequent attacks, to add a preventive. Our guide to medication-overuse headache covers how this happens and how to step back from it.

Rizatriptan is not safe for everyone, mainly because narrowing blood vessels is dangerous for some hearts and arteries. The label rules it out for people with the following:

• Coronary artery disease, angina, or a history of heart attack
• Uncontrolled high blood pressure
• A history of stroke or transient ischemic attack
• Peripheral vascular disease, including reduced blood flow to the gut
• Hemiplegic migraine or migraine with brainstem aura, two rare types
• Use of an ergot drug or another triptan within the past 24 hours
• Use of a monoamine oxidase inhibitor (MAOI) within the past two weeks

This list is why rizatriptan needs a prescription and why a clinician screens for heart risk before starting it. Some of these are firm blocks; others depend on a person's full picture, which is the clinician's call.

Rizatriptan and sumatriptan are close cousins that work about as well, with rizatriptan tending to act a bit faster and to leave more people pain-free. Both are selective 5-HT1B/1D agonists, both stop an attack in progress, and both carry the identical heart-related contraindications. In the meta-analysis that used sumatriptan 100 mg as the benchmark, rizatriptan 10 mg came out ahead on the two-hour response and on consistency across attacks, with similar tolerability (Ferrari 2001).

The trade-off runs the other way on forms. Sumatriptan comes as a tablet, a nasal spray, and an injection, and the injection is the fastest-acting triptan of all, useful when an attack hits hard or with heavy vomiting. Rizatriptan comes only as a swallowed tablet and a melt, both taken by mouth. So rizatriptan often wins on oral speed and pain-free rates, while sumatriptan offers routes that bypass the stomach. We line up the two choices in detail in sumatriptan versus rizatriptan.

People also respond differently from one triptan to the next, so a drug that disappoints one person can work well for another. Switching between them is about tolerability, speed, and the form that fits, not about getting around the shared cautions.